DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the ...
It has had strong momentum since November, but there is still plenty of upside left.
DexCom reports better-than-expected preliminary results for the fourth quarter.
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...
DexCom, Inc.’s (NASDAQ:DXCM) third-quarter 2025 revenue reached $1.209 billion, beating the analyst consensus estimate of $1.179 billion. Revenue grew 22% year-over-year on a reported basis and 20% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results